is an autosomal recessive disease caused by a deficiency of N-acetylgalactosamine 4-sulfatase (4S) leading to the lysosomal accumulation and urinary excretion of dermatan sulfate. MPS VI has also been described in the Siamese cat. As an initial step toward enzyme replacement therapy with recombinant feline 4S (rf4S) in MPS VI cats, the feline 4S cDNA was isolated and expressed in CHO-KI cells and rf4S was immunopurified from the culture medium. SDS-polyacrylamide gel electrophoresis analysis showed that the precursor form of immunopurified rf4S was a 66-kDa polypeptide that underwent maturation to a 43-44-kDa polypeptide. Endocytosis of rf4S by cultured feline MPS VI myoblasts was predominantly mediated by a mannose 6-phosphate receptor and resulted in the correction of dermatan sulfate storage. The mutation causing feline MPS VI was identified as a base substitution at codon 476, altering a leucine codon to a proline (L476P). The L476P allele displayed no detectable 4S activity when expressed in CHO-KI cells and was observed only as a "precursor" polypeptide that was not secreted into the medium. Identification of the mutation has allowed the development of a rapid PCR-based screening method to genotype individuals within the cat colony.
and soft tissue involvement. The central nervous system does not appear to be affected, even in individuals with clinically severe MPS VI (3) .
The concept of gene and enzyme replacement therapy involves the supplementation of the missing gene product into the patient's circulation by transplantation of autologous genetically modified cells that express the missing gene (gene therapy) or by infusion of recombinant enzyme (enzyme replacement therapy) (4, 5) . The MPSs are good candidates for therapy protocols as most, if not all, cells appear to be capable of endocytosing MPS enzymes via the mannose 6-phosphate (M6P) receptor pathway (6) . Previous in vitro studies with cultured human MPS VI fibroblasts have demonstrated that recombinant human 4S (rh4S) is efficiently endocytosed by the M6P receptor and that only small amounts of the enzyme are required to correct the storage defect (7) .
MPS VI has also been described in the Siamese cat, and a colony has been established to study the progression of the disease and possible therapies (8) . The MPS VI cat is an excellent model for evaluating therapy protocols. The pathophysiology of feline and human MPS VI is similar, thereby enabling results from the animal studies to be used to optimize the design of clinical trials in humans. Because there is no central nervous system involvement in MPS VI, there is no requirement for the therapeutic protein to cross the blood-brain barrier, thereby enabling most sites of pathology to be potentially accessible to circulating enzyme.
The isolation of the human 4S cDNA and expression of rh4S have been described previously (7, 9, 10) . The efficacy of rh4S administered intravenously to MPS VI cats is currently being investigated. Preliminary results have demonstrated variable improvement in skeletal and soft tissue pathology. However, one cat displayed a significant antibody titer to rh4S, which may have reduced the availability and subsequent efficacy of rh4S in these studies (11) . This paper describes the isolation and expression of the feline 4S (f4S) cDNA and demonstration of its functional integrity as an initial step toward f4S replacement therapy in the MPS VI cat. A mutation causing feline MPS VI was also identified in this study by molecular characterization of the MPS VI f4S cDNA; it allowed the development of a rapid PCR-based screening method to genotype animals within our MPS VI cat colony. The identified 4S missense mutation displayed no detectable activity when expressed in cell culture.
EXPERIMENTAL PROCEDURES
Cloning the Feline 4S cDNA-A feline heart cDNA library (Uni ZAP XR library, Stratagene) was screened for 4S cDNA clones using a 1.6-kilobase human 4S cDNA (9) as a probe. The probe was labeled with [␣- 32 P]dCTP using the Megaprime DNA labeling kit (Amersham Corp.). A partial 4S cDNA was isolated and rescued into the phagemid pBluescript SK Ϫ as recommended by the supplier. The remaining 4S
coding sequence was PCR amplified from normal feline testes first strand cDNA. First strand cDNA synthesis (20 l reaction volume) was carried out at 37°C for 1 h in the presence of 1 ϫ AMV reverse transcriptase buffer (50 mM Tris-HCl, pH 8. Table I . PCR products were purified using a QIAquick PCR purification kit (QIAGEN).
Culture and Electroporation of CHO-KI Cells-The normal and mutagenized f4S cDNA were excised from pBluescript SK Ϫ with EcoRI and cloned into the expression vector pEFNeo (12) placing the cDNA under the transcriptional control of the human polypeptide chain elongation factor-1␣ (EF1␣) gene promoter. Large-scale plasmid preparations of pEFNeo, pEFNeof4S, and pEFNeoL476P (25 g) were electroporated into CHO-KI cells as described previously (7), with the following modifications. Electroporated cells were grown in nonselective medium for 24 h and then subcultured 1:5 into medium containing 0.75 mg/ml G418 (neomycin). G418 selection resulted in the appearance of approximately 250 colonies per transfection. Selected cells were maintained in 0.5 mg/ml G418.
Immunoprecipitation-G418-resistant mass cultures of electroporated CHO-KI cells were grown to confluence in 75-cm 2 tissue culture flasks and then metabolically labeled with 10 Ci/ml 3 H-labeled leucine (168 mCi/mmol; DuPont NEN) for 24 h. Growth medium was collected and clarified by centrifugation (2000 ϫ g for 3 min at 4°C). Cells were harvested and resuspended in solubilization buffer (phosphate-buffered saline containing 1% (w/v) sodium deoxycholate, 0.1% (v/v) SDS, 0.5% (v/v) Nonidet P-40). Growth medium and cell lysates were immunoabsorbed using a rabbit polyclonal antibody raised against rh4S (1/ 100,000 titer). Rabbit ␣h4S was added to each medium or lysate sample (1 l/ml) and incubated at 4°C for 24 h. Pansorbin cells (Calbiochem; 75 l) were added to each sample, incubated at 4°C for a further 24 h and then sedimented by microcentrifugation. The pellets, which contained the 4S antibody-protein A complexes, were washed four times in solubilization buffer and once in distilled water and then were resuspended in sample buffer (1% (w/v) SDS, 4 M urea, 80 mM Tris-HCl, pH 6.8, 0.1% (w/v) bromphenol blue). Samples were boiled for 5 min and centrifuged at 12,000 ϫ g for 1 min to pellet the Pansorbin cells, and the supernatant was analyzed via SDS-PAGE (19) and autoradiography.
Determination of 4S Expression-Venous blood was collected from cats in lithium heparin tubes. Leucocytes were isolated within 8 h using the dextran sedimentation method (13) followed by hypotonic saline washes to remove remaining red blood cells. Leucocyte lysates were prepared by seven cycles of freeze-thaw in 0.1% (v/v) Triton X-100. Cultured myoblasts and electroporated CHO-KI cells were harvested with 10% (v/v) trypsin-versene (Life Technologies, Inc.) and washed with phosphate-buffered saline. Cell lysates were prepared by seven cycles of freeze-thaw in 0.5 M NaCl, 20 mM Tris-HCl, pH 7. Growth medium and cell lysates were clarified by centrifugation and assayed for 4S activity using the fluorogenic substrate 4-methylumbelliferyl sulfate (4MUS) (14) . The 4MUS substrate assay is a nonspecific assay that detects total arylsulfatase (A, B, and C) activity. Therefore, arylsulfatase B (4S) activity was also determined using the 4MUS substrate assay following immune capture of 4S with a rabbit anti-human 4S polyclonal antibody (15) . Alternatively, samples were specifically assayed for 4S using the radiolabeled trisaccharide substrate GalNAc4S-glucuronic acid (GlcA)-galitolNAc4S derived from rat chondrosarcoma chondroitin 4-sulfate (16) . Total cellular protein was quantified using the Bio-Rad or Lowry (17) protein assays. ␤-Hexosaminidase activity was determined by using the fluorogenic substrate, 4-methylumbelliferyl-2-acetamido-2-deoxy-␤-D-glucopyranoside (18) .
Isolation and Culture of Feline Myoblasts-All animals used in these studies were established from heterozygous cats (MPS VI-3 family) obtained from Mark Haskins (University of Pennsylvania, Philadelphia, PA) (8) . Myoblasts were isolated from normal and MPS VI feline skeletal muscle tissue. Muscle biopsies (0.2-0.5 g) were obtained from the vastus lateralis muscle, washed with Hanks' balanced salt solution, minced into 1-mm 3 pieces, and then incubated at 37°C for 15 min with continual agitation in the same Hanks' solution containing 0.1% (w/v) Pronase (Boehringer Mannheim). Released myoblasts and undigested tissue were centrifuged and resuspended in fresh 0.1% Pronase solution. This process was repeated three times (i.e. a total of four 15-min incubations at 37°C). Released myoblasts were seeded into six-well flat-bottom culture plates precoated with fibronectin (2 g/cm 2 , Sigma) and maintained at 37°C in 5% CO 2 . The growth medium was Ham's F-10 medium supplemented with antibiotics, 20% (v/v) FCS, 20 g/ml insulin, 8 ng/ml basic fibroblast growth factor, and 0.1 M dexamethasone. To determine cell purity, myoblast preparations were stained for desmin using a rabbit monoclonal antibody raised against porcine desmin (Sigma) as described previously (19) . Myoblast fusion was shown to occur when the FCS concentration in the growth medium was reduced to 10% (v/v) or when cells were over-confluent.
Correction of GAG Storage in MPS VI Myoblasts and Endocytosis of rf4S-Recombinant f4S was obtained from a high-expressing CHOf4S cell line (CHOf4S-2) cultured in Ham's F-12 medium supplemented with antibiotics and 10% (v/v) FCS. The CHOf4S-2 medium was clarified by centrifugation and shown to contain rf4S with an activity of 231 nmol/min/ml when assayed directly with 4MUS. Myoblasts isolated from normal and MPS VI cats were grown to confluence in 25-cm 2 flasks. Cells were labeled for 24 h with 15 Ci/ml Na 2 35 SO 4 (543 mCi/mmol; DuPont NEN) in antibiotic-free medium. Labeled cells were rinsed with medium and then exposed to 2.6 nmol/min/ml rf4S or 26 nmol/min/ml rf4S (derived from CHOf4S-2-conditioned medium) for 48 h. In addition to rf4S, some groups of cells were also exposed to 5 mM M6P. As controls, a group of normal and MPS VI myoblasts were labeled with Na 2 35 SO 4 and then exposed to 10% (v/v) CHO-KI-conditioned medium for 48 h. Cell lysates were prepared and assayed for total protein, ␤-hexosaminidase, and 4S activity.
Large-scale Production and Characterization of rf4S-CHOf4S-2 cells were inoculated into two two-layer cell factories (Nunc; 1200 cm 2 ) in COONS/Dulbecco's modified Eagle's medium supplemented with 5% (v/v) FCS and antibiotics. Once the cells had reached confluency, the medium was replaced with COONS/Dulbecco's modified Eagle's medium, 2% (v/v) FCS plus antibiotics. In some instances CHOf4S-2 cells were also grown in FCS-free COONS/Dulbecco's modified Eagle's medium. To maximize secretion of precursor rf4S, NH 4 Cl (final concentration, 10 mM) was added to the medium (20) . Conditioned medium was collected every 4 days, clarified by centrifugation (2000 ϫ g for 5 min at 4°C), and stored at 4°C. Recombinant f4S was immunoaffinity-purified directly from conditioned medium essentially as described in Ref. 7 with the modification that 4S-F58.3 Affi-Gel (21) was used in place of 4S-F4.1 Affi-Gel. 4S-F58.3 and 4S-F4.1 are both monoclonal antibodies raised against 4S purified from human liver. Only 4S-F58.3 was found to cross-react with rf4S and was therefore used for immunopurification. To estimate apparent subunit size, immunopurified-rf4S was analyzed under reducing and nonreducing conditions by SDS-PAGE (12% acrylamide) (22) . Western blot analysis (23) of immunopurified rf4S and rf4S present in concentrated FCS-free conditioned medium was also performed using a rabbit polyclonal antibody to rh4S (1/800,000 titer) (14) . Native molecular mass was determined using a fast protein liquid chromatography system as described previously (24) . Kinetic data (K m , V max , specific activity, and pH optima) were obtained using 4MUS and the trisaccharide substrate as described in Ref. 16 .
Mutation Analysis of the MPS VI f4S cDNA-PCR products were amplified from normal, heterozygote, and MPS VI fibroblast first strand cDNA template and directly sequenced using a fmol sequencing kit (Promega). PCR conditions were 40 cycles of the following: denaturation at 94°C for 30 s, annealing at 58°C for 30 s, and extension at 72°C for 45 s. The sequence and position of oligonucleotides used for PCR or PCR sequencing are listed in Table I . PCR reactions were carried out in 100-l volumes and contained 1 ϫ PCR buffer (Biotech International Limited), 2.5 mM MgCl 2 , 10% dimethyl sulfoxide, 400 M dNTPs, 330 ng of each oligonucleotide (Table I) , and 1.5 units of Taq DNA polymerase (Biotech). All PCR products were gel purified prior to sequencing.
Screening of the MPS VI Cat Colony for the Mutant Allele-Allelespecific oligonucleotides (ASOs) were designed for the region of f4S containing the mutation and are listed in Table I (f4S-Leu 476 and f4S-Pro 476 ). Venous blood from cats was spotted onto Guthrie cards (25) . Punched discs (3 mm in diameter) were eluted in 1 ϫ PCR buffer (Biotech), 2.5 mM MgCl 2 at 4°C for 30 min then at 99°C for 15 min. Samples were then subjected to the same PCR conditions as described above, using Taq DNA polymerase and oligonucleotides f4S-7 and f4S-9 (see Table I ). One to 3 l of each PCR reaction was spotted onto GeneScreen Plus membranes (DuPont NEN) in duplicate and probed with either f4S-Leu 476 or f4S-Pro 476 32 P-labeled oligonucleotides (Table  I) . Hybridization was carried out at 42°C in 6 ϫ SSC, 0.05% (v/v) sodium pyrophosphate, 100 g/ml herring sperm DNA, and 0.1% (v/v) SDS. Membranes were washed for 5 min at 55°C in 2 ϫ SSC, 0.1% (v/v) SDS and autoradiographed. Alternatively, the genotypes of cats were determined via restriction analysis of PCR products with HaeIII. The presence of the mutant Pro 476 allele (CCC) results in the introduction of a HaeIII site at nucleotide 1427 (26) .
Construction of L476P-To determine whether the L476P mutation affects f4S activity, the Pro 476 allele was engineered into the normal f4S cDNA sequence. Nucleotides 1148 -1608, as numbered in the published f4S sequence (26) , were PCR amplified from heterozygote fibroblast first strand cDNA using oligonucleotides 4SP-31 and f4S-11 (600 ng; see Table I ) and 4.2 units of UlTma DNA polymerase (Perkin-Elmer). The PCR product was digested with SphI and BclI, gel purified, and cloned into the f4S cDNA linearized with the same restriction endonucleases. Nucleotides 1348 -1608 of 24 individual clones were PCR amplified using primers f4S-9 and f4S-11 (see Table I ). HaeIII restriction analysis of each PCR product was used to identify f4S clones containing the mutant Pro 476 allele. Mutant f4S clones were sequenced with Sequenase Version 2 (Amersham Corp.), and a clone that contained the Pro 476 allele and no other changes was then excised from pBluescript SK Ϫ with EcoRI and cloned into the mammalian expression vector pEFNeo (pEFNeoL476P) (12) . Restriction analysis was used to identify recombinants containing the mutated construct in the correct orientation.
RESULTS AND DISCUSSION
Isolation of the f4S cDNA-A partial f4S cDNA was isolated after screening 2.6 ϫ 10 6 clones from a feline heart cDNA library. DNA sequence analysis showed that the f4S cDNA clone was missing the first 417 and last 97 base pairs of published coding sequence (26) . To construct the full-length 4S cDNA, the first 462 and last 261 base pairs of published f4S coding sequence (26) were PCR amplified from normal (unrelated to our cat colony) feline testes first strand cDNA (see "Experimental Procedures"). Primer f4S1, which was used to amplify the 5Ј PCR product (see Table I ), contained the Kozac sequence 5ЈGCCACC3Ј immediately upstream of the ATG codon in an attempt to ensure efficient translation (27) . The 5Ј PCR product was digested with EcoRI and NdeI, and the 3Ј PCR product was digested with BclI and XhoI. Both PCR products were then gel purified and cloned into the partial f4S cDNA. The 5Ј and 3Ј noncoding regions of f4S were not isolated. DNA sequence analysis identified two discrepancies with the previously published f4S sequence (26) . Nucleotide 119, which was PCR-derived from normal testes first strand cDNA, was identified as A in our sequence analysis, indicating the alteration of codon 40 from glycine (GGA) to glutamic acid (GAA). Direct sequencing of several PCR products amplified from normal, mutant, and heterozygote first strand cDNA demonstrated that the identified discrepancy was not a PCR cloning artifact. Codon 476, which was clone-derived, was identified as a leucine codon (CTC). The published f4S sequence encodes proline (CCC) at codon 476 (26) .
Expression of the f4S cDNA-The f4S cDNA was cloned into the expression vector pEFNeo (12) . Restriction analysis was used to identify recombinants containing the f4S cDNA in the correct orientation. One such construct (pEFNeof4S) was electroporated into CHO-KI cells. Twenty-four individual G418-resistant clones containing the pEFNeof4S expression construct were isolated, grown to confluence and assayed directly for total arylsulfatase activity using 4MUS. Arylsulfatase activity present in medium conditioned for 18 h ranged from background (0.57 nmol/min/ml) to 10.17 nmol/min/ml. The highest expressing clone (CHOf4S-2) was expanded and used for the large-scale production and characterization of rf4S (see below). After 3 days, untransfected CHO-KI and CHOf4S-2 cell culture media contained arylsulfatase activities of 0.44 nmol/ min/ml and 66.5 nmol/min/ml, respectively.
Correction of GAG Storage in MPS VI Myoblasts with rf4S-
The storage of undegraded, sulfated GAGs in feline MPS VI myoblasts was analyzed by measuring the accumulation of material in cells metabolically labeled with Na 2 35 SO 4 (see "Experimental Procedures"). It is likely that the majority of intracellular 35 S radioactivity measured in these studies results from the lysosomal accumulation of sulfated GAGs. Myoblasts isolated from a MPS VI cat were shown to store approximately 7 times as much intracellular 35 S-labeled GAGs as normal myoblasts (Table II) . Previous experiments have demonstrated Primers in groups 1 and 2 were used to PCR amplify f4S sequence from normal testes first strand cDNA template. Both PCR products were then cloned into the partial f4S cDNA to complete the coding sequence. Primers in groups 3 and 4 were used to amplify f4S sequence from normal, heterozygote, and MPS VI fibroblast first strand cDNA template. All primers except those in group 5 were used for sequencing. A PCR approach was taken to engineer the Pro 476 allele into the wild-type f4S sequence using primers 4SP-31 and f4S-11 and heterozygote fibroblast first strand cDNA as template. The positions of primers in the f4S cDNA sequence are according to Fig. 2 this elevated level of GAG storage to be reproducible. 2 CHOf4S-2-conditioned medium was used as a source of rf4S in the correction studies. The presence of rf4S in the MPS VI myoblast culture medium at 2.6 and 26 nmol/min/ml both resulted in the clearance of 35 S-labeled GAGs to levels comparable with those seen in normal myoblasts. Levels of intracellular 4S activity in corrected MPS VI myoblasts were shown to be 3-18-fold above normal myoblast 4S levels. The activity of the lysosomal enzyme ␤-hexosaminidase in cultured myoblasts was not affected by the endocytosis of rf4S. Control MPS VI myoblasts cultured in the presence of CHO-KI-conditioned medium exhibited no correction of GAG storage. The addition of 5 mM M6P to the culture medium substantially reduced the uptake of rf4S, suggesting that endocytosis of rf4S in MPS VI myoblasts is predominantly mediated by a M6P receptor (Table II) .
Large-scale Production and Characterization of rf4S-Largescale production of rf4S from CHOf4S-2 cells yielded 3-4 mg/ liter of culture medium. Total recovery of enzyme activity from the 4S-F58.3 Affi-Gel was approximately 56%, of which 40% was unbound, whereas the remaining 16% was bound and subsequently eluted in 0.1 M sodium citrate, 2 M NaCl, 10% (v/v) glycerol, pH 4.0. Reapplication of the unbound rf4S resulted in an additional 10% binding to the Affi-Gel, and this was eluted as described above. Exceeding the binding capacity of the column is excluded as an explanation for this observation becuase, routinely, 3 mg of rh4S can be bound to 4S-F58.3 Affi-Gel and in this case binding of only 1 mg of rf4S was attempted. A more likely explanation is that the binding of rf4S to 4S-F58.3 Affi-Gel is weaker than that of rh4S under the same buffer conditions. SDS-PAGE and Western blot analysis indicated that rf4S immunopurified from CHOf4S-2 medium predominantly contained the 66-kDa precursor form, which is identical to that of rh4S (7) (Fig. 1) . Other studies undertaken in this laboratory to characterize 4S purified from either human or feline liver (14, 28) corroborate these findings. However, fast protein liquid chromatography analysis showed rf4S to fractionate at a molecular mass of 30 -32 kDa (data not shown). This molecular mass was consistently observed when rf4S medium or immunopurified rf4S were applied to the column. In contrast, rh4S in the same system and under the same buffer conditions fractionated at a molecular mass of 67 kDa. We postulate that rf4S is interacting with the fast protein liquid chromatography column matrix and is thus being retarded. The reason for this interaction is not known. With the exception of a very minor band at 100 kDa (Fig. 1B) observed on a Western blot, we have found no evidence for the existence of the predominant form of f4S as a homodimer, as was previously suggested (29, 30) .
A smaller amount (approximately 30%) of the mature form (43 and 11 kDa) was also present in the immunopurified-rf4S preparation. By analogy to rh4S, in which the smaller subunit was resolved into two disulfide-linked subunits of 7 and 8 kDa as described in Ref. 31, 3 we anticipate that the smaller subunit of rf4S also comprises these two subunits. Under nonreducing conditions on an SDS-polyacrylamide gel, the mature form of immunopurified-rf4S migrated as a 53-kDa polypeptide that is marginally smaller than the mature form of rh4S (55 kDa). Under reducing conditions, the subunits of the mature form of rh4S (44 and 12 kDa) were also slightly larger than those of rf4S (Fig. 1A) . Western blot analysis of nonreduced rf4S, when probed with rabbit anti-rh4S polyclonal antibody, again demonstrated that the predominant molecular forms of rf4S were the 66-kDa precursor and the 56 -58-kDa mature forms, with the mature form of rf4S being slightly smaller than the mature 2 G. Yogalingam, unpublished observation.
3 J. Bielicki, unpublished observation.
FIG. 1. SDS-PAGE and Western blot analysis of rf4S immunopurified from CHOf4S-2 medium.
A, SDS-PAGE. Lanes 1, 2, and 3 are molecular mass standards, immunoaffinity-purified rf4S, and rh4S respectively, electrophoresed under reducing conditions (0.1 mM dithiothreitol). Lanes 4 and 5 are rf4S and rh4S, respectively, electrophoresed without dithiothreitol. The gel was stained with Coomassie Blue R-250 (Sigma). B, Western blot. Lanes 1, 2, 3, and 4 are molecular mass standards, immunoaffinity-purified rf4S, rf4S from conditioned medium, and immunoaffinity-purified rh4S, respectively, electrophoresed under reducing conditions (0.1 mM dithiothreitol). Lanes 5, 6, and 7 are identical to lanes 2, 3, and 4, respectively, but electrophoresis was performed without dithiothreitol. In both A and B the molecular mass standards (in kDa; lane 1) and the calculated molecular masses of rf4S and rh4S are indicated with arrows. form of rh4S (Fig. 1B) . The slight discrepancy in size between the nonreduced mature forms of rh4S and rf4S in Fig. 1, A and B, is due to different molecular mass standards used in the SDS-PAGE and Western blot analysis. Kinetic data (Table III) using 4MUS as substrate indicate that rf4S and rh4S have identical pH optima (pH 5.6) and similar K m (1.57 and 1.18 mM, respectively), V max (35.2 and 48.5 mol/min/mg, respectively), and specific activity (27.8 and 39.4 mol/min/mg, respectively) values. At a pH optimum of 2.85 in 50 mM sodium formate buffer, these catalytic parameters were also similar for both rf4S and rh4S toward the trisaccharide substrate (Table III) .
Promising results have been obtained thus far with the systemic administration of rh4S to MPS VI cats (11) . Because the physical and kinetic properties of rh4S and rf4S are similar, it is likely that rf4S replacement therapy in MPS VI cats will also yield beneficial results. When using animal models to evaluate therapy protocols, it may be advantageous to use species-specific material in an attempt to avoid the complication of immunological responses to foreign antigens. One of the MPS VI cats placed on rh4S replacement therapy displayed a significant antibody titer to rh4S (11) . Whether an antibody response is elicited to f4S following rf4S administration to MPS VI cats remains to be determined.
Mutation Analysis of the MPS VI Cat Colony-In an attempt to identify the mutation causing feline MPS VI, PCR products amplified from normal, heterozygote, and MPS VI fibroblast first strand cDNA were sequenced and compared. All PCR products were shown to encode glutamic acid at codon 40 in accordance with the f4S cDNA clone that was isolated in this study. At nucleotide 1427, a T 3 C base substitution was identified in the MPS VI f4S sequence, which results in a change at codon 476 from CTC (leucine) to CCC (proline) (L476P). No other changes were identified between the normal and mutant f4S coding sequences. The heterozygote f4S cDNA contained both T and C at nucleotide 1427 (Fig. 2) . A confusing point in the sequence analysis was that codon 476 of the f4S published sequence (26) encodes proline (CCC; i.e. the mutant allele). This result suggested that the previously published f4S sequence was incorrectly assigned as wild-type sequence and may in fact be feline MPS VI f4S sequence.
Expression of L476P rf4S and Comparison with rf4S-To determine whether L476P affects f4S activity, the Pro 476 allele was engineered into the normal f4S cDNA sequence (see "Experimental Procedures"). The L476P f4S cDNA and normal f4S cDNA were cloned into the mammalian expression vector pEFNeo (12) . CHO-KI cells electroporated with pEFNeoL476P displayed 4S activities similar to those present in control pEFNeoelectroporated CHO-KI cells (3.47 pmol/min/mg). CHO-KI cells electroporated with pEFNeof4S showed 4S activities toward 4MUS ranging from 9730 to 20240 pmol/min/mg total cellular protein (Table IV) . Medium harvested from CHOL476P and CHOf4S cells after 24 h contained 0.6 and 40 pmol/min/ml 4S, respectively. Background 4S activity present in CHOpEFNeoconditioned medium was 0.6 pmol/min/ml (Table IV) .
G418-resistant mass cultures of electroporated CHO-KI cells were radiolabeled for 24 h with 3 H-labeled leucine. Recombinant f4S and L476P rf4S, present in solubilized cell lysates and culture medium, were characterized by immunoprecipitation and SDS-PAGE. Recombinant f4S immunoprecipitated from CHOf4S cell lysates migrated under reducing conditions predominantly as a mature 44-kDa polypeptide. A smaller amount of precursor polypeptide (64 kDa) was also detected (Fig. 3,  lanes 7-10) . Enzyme immunoprecipitated from CHOf4S medium predominantly contained a precursor polypeptide (66 kDa) and a smaller amount of mature 44-kDa polypeptide (Fig.  3, lanes 14 and 15) . The rf4S precursor polypeptide secreted into CHOf4S culture medium (66 kDa) was slightly larger than the precursor polypeptide present in CHOf4S cell lysates (64 kDa). This may be due to differences in carbohydrate modification between the secreted and intracellular forms of precursor rf4S.
FIG. 2.
Identification of L476P by DNA sequencing. PCR products encoding f4S were amplified from mutant (A), normal (B), and heterozygote (C) first strand cDNA and sequenced directly. Nucleotides 1422-1432, as numbered in the published f4S sequence (26) , are shown. The T 3 C base substitution at nucleotide 1427 in the mutant sequence (A) is indicated by an arrow. The heterozygote PCR product (C) contains C and T at nucleotide 1427.
TABLE III Comparison of catalytic properties of rf4S and rh4S
Recombinant f4S and rh4S were immunoaffinity purified directly from conditioned medium using 4S-F58.3 Affi-Gel. K m , V max specific activity, and pH optima were determined using 4MUS and the trisaccharide substrate. L476P rf4S immunoprecipitated from CHOL476P cell lysates was detectable only as a precursor 64-kDa polypeptide (Fig. 3, lanes 3-6) . L476P did not appear to be cleaved to the mature 43-44-kDa form or secreted into the medium (Fig. 3,  lanes 12 and 13) . Densitometric analysis of the precursor polypeptide bands in cell lysates revealed a 5-fold elevation of the L476P rf4S precursor when compared with normal rf4S precursor (Fig. 3, lanes 3-6 versus lanes 7-10) . The 5-fold elevation in L476P rf4S precursor polypeptide may correspond to newly synthesized protein that is selectively retained within the endoplasmic reticulum due to incorrect folding and is subsequently degraded. If the mutant form of f4S does not exit the endoplasmic reticulum, it is possible that MPS VI cats will not be tolerant of the feline form of 4S in enzyme replacement protocols. Alternatively, L476P rf4S may be synthesized as an unstable precursor polypeptide that is transported to the lysosome and rapidly degraded in the hydrolytic environment.
The L476P missense mutation may provide some insight into the functional domains of 4S. The introduction of L476P into the f4S sequence resulted in overall reduced amounts of mutant protein with no detectable 4S activity being expressed in cell lysates. Because residue 476 of f4S is conserved among six other sulfatases it is tempting to speculate that this residue of f4S is required for the functional integrity of the protein (32) .
Detection of L476P by ASO-Cats were screened for the Leu 476 and Pro 476 alleles by ASO hybridization to determine whether L 476 P was linked to the mutation in the MPS VI cat colony. The genotypes of 111 cats were determined using this screening method. L476P was not detected in 34 normal (unrelated to our cat colony) cat PCR samples but was homozygous in all 58 MPS VI cat PCR samples analyzed. In addition, 19 obligate heterozygote carriers for the L476P allele were identified by ASO hybridization. HaeIII restriction analysis of PCR products was also used to identify the L476P allele. Fig. 4 B, PCR products encoding f4S were amplified from cat blood samples and digested with HaeIII to demonstrate the T 3 C base substitution. Two restriction fragments (79 and 199 base pairs) were generated from HaeIII digestion of homozygote mutant PCR products (lanes 2 and 5). Heterozygote PCR products were partially digested with HaeIII ( lanes 1, 4, and 7) . Normal cats only displayed the 278-base pair undigested PCR product following HaeIII restriction (lanes 3 and 6) . C, alternatively, the genotypes of cats were determined by ASO hybridisation of f4SLeu 476 and f4SPro 476 oligonucleotides. f4SPro 476 hybridized very strongly to homozygote PCR products (lanes 2 and 5). f4SLeu 476 hybridized to normal PCR products with high affinity (lanes 3 and 6) . Both ASOs hybridized to heterozygote PCR products (lanes 1, 4, and 7) . In summary, the f4S cDNA was isolated and expressed in CHO-KI cells. A high expressing CHO-KI cell line (CHOf4S-2) was used for the large-scale production and characterization of rf4S. Endocytosis of rf4S via a M6P receptor resulted in the clearance of sulfated GAGs from cultured feline MPS VI myoblasts thereby demonstrating the functional integrity of rf4S. The isolation and expression of the f4S cDNA will now permit the evaluation of rf4S replacement therapy in the MPS VI cat. Equally important to this study was the identification of L476P as a mutant 4S allele in the MPS VI cat colony. Identification of L476P has allowed the development of a rapid PCR-based screening method to genotype animals within the colony at birth.
